US 12,029,784 B2
BCMA chimeric antigen receptors
Richard Morgan, Center Harbor, NH (US); and Kevin Friedman, Melrose, MA (US)
Assigned to 2seventy bio, Inc., Cambridge, MA (US)
Filed by 2seventy bio, Inc., Cambridge, MA (US)
Filed on Oct. 23, 2020, as Appl. No. 17/079,006.
Application 17/079,006 is a continuation of application No. 16/837,610, filed on Apr. 1, 2020, granted, now 11,633,463.
Application 16/837,610 is a continuation of application No. 16/504,859, filed on Jul. 8, 2019, granted, now 10,646,558, issued on May 12, 2020.
Application 16/504,859 is a continuation of application No. 15/535,365, granted, now 10,383,929, issued on Aug. 20, 2019, previously published as PCT/US2015/064269, filed on Dec. 7, 2015.
Claims priority of provisional application 62/200,505, filed on Aug. 3, 2015.
Claims priority of provisional application 62/091,419, filed on Dec. 12, 2014.
Prior Publication US 2021/0077603 A1, Mar. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01)
CPC A61K 39/0011 (2013.01) [C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2878 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/585 (2013.01); C07K 2317/622 (2013.01); C07K 2319/32 (2013.01); C12N 2740/15043 (2013.01); C12N 2830/15 (2013.01)] 50 Claims
 
1. A method of treating a B cell malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of human immune effector cells that express a chimeric antigen receptor (CAR) comprising the amino acid sequence set forth in SEQ ID NO: 9.